Esphera SynBio, a pre-clinical stage synthetic biology company, has launched a new project aimed at enhancing the efficacy of ...
Grants Verdiva Bio exclusive global rights (excluding Greater China and South Korea) to develop and commercialize its ...
A Phase 2 trial of MTX-463 in idiopathic pulmonary fibrosis expected in 1H 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback